ClinicalTrials.gov
public full text
Public Domain
Evaluation of the Efficacy of a Dermocosmetic Product RT00401-GO0046 on Atopic Dermititis Severity in Subjects With Mild Atopic Dermatitis Versus Placebo
The aim of this study is to evaluate the RT00401- GO0046 formula on atopic dermititis severity in subjects with mild atopic dermatitis versus placebo on 26 subjects. The objectives of this study are: * To evaluate the clinical efficacy of the RT00401-GO0046 cream compared to RT00401-GA0677 placebo cream on AD severity of tested areas and flare-up onset. * To evaluate the effect of the RT00401-GO0046 cream on microbiota diversity and other pharmaco-clinical biomarkers with respective techniques on skin surface in subjects with AD compared to the effect of the RT00401-GA0677 placebo cream. * To illustrate the effect of the RT00401-GO0046 cream with photos of the tested areas. This study will be conducted as an intra-individual, comparative, randomized, monocentric, investigator-blinded study, with 3 visits are planned: * Visit 1 (D1): Inclusion and 1st products application * Visit 2 (D29 +/- 2 days): 1-month follow-up visit * Visit X (Suspected flare-up +/- 2 days): End-of-study visit if AD flare-up is confirmed * Visit 3 (D85 +/- 3 days): End-of-study visit This clinical study is designed as an investigator-blinded study. Participants will be required to apply two different products, one on each side: Product A and Product B. One of these products is the "test product" RT00401 Formula GO0646, and the other is the "control product" RT00401 Formula GA0677. However, participants will not know which product is which. The randomization will determine the side on which each product is applied (Product A on the right and Product B on the left, or vice versa). The product tubes will be identical, ensuring that neither the participants nor the investigator will know which product is the test product or the control product. This blinding ensures that neither the participants nor the investigator will be influenced by the nature of the products applied, thereby enhancing the robustness and objectivity of the study results.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis#1171290
- Severity bands for atopic dermatitis measures: analysis from adult dupilumab randomized clinical trials / Andreas Wollenberg, Eric L. Simpson, Yael A. Leshem, Alain Taïeb, Norito Katoh, Jingdong Chao, Ana B. Rossi, Amy H. Praestgaard#783932
- Achieving minimal disease activity in atopic dermatitis is associated with fewer flares, reduced healthcare resource utilization, and improved disease control: analysis from the real-world MEASURE-AD study#1015167
- The Role of IL-22/IL-22BP Axis in Atopic Dermatitis#1138955
- Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis#847710
Record · ID 905264
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive